Patents by Inventor John Lippincott

John Lippincott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 11873339
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: January 16, 2024
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Antibodies to TIGIT
    Patent number: 11820824
    Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: November 21, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Kelsey Sivick Gauthier, Nigel Pelham Clinton Walker, Xiaoning Zhao, John Lippincott
  • BTLA-BINDING ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE
    Publication number: 20230340123
    Abstract: The invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Application
    Filed: July 10, 2022
    Publication date: October 26, 2023
    Inventors: Brian A. ZABEL, John A. LIPPINCOTT, Yayue ZHENG, Megha Vaman RAO, Miao TAN, David P. MEININGER
  • Anti-CD115 antibodies
    Patent number: 11753478
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 12, 2023
    Assignee: ABLEXIS, LLC
    Inventors: John Lippincott, Dana Duey
  • Anti-claudin 18.2 antibodies
    Patent number: 11485782
    Abstract: Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 1, 2022
    Assignee: Beijing Xuanyi Pharmasciences Co., Ltd.
    Inventors: Yuntao Song, Yi Ding, Chen Dong, Zhiwei Li, John Lippincott, Ping Hui Szu
  • ANTI-CD47 ANTIBODIES
    Publication number: 20220267440
    Abstract: The present invention provides anti-CD47 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, ischemic-reperfusion injury, and other diseases.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: John Lippincott, Dana Duey, Larry Green
  • BTLA-binding antibodies for modulating immune response and treating disease
    Patent number: 11384146
    Abstract: The invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: July 12, 2022
    Assignees: Curia IP Holdings, LLC, TRIANNI, Inc.
    Inventors: Brian A. Zabel, John A. Lippincott, Yayue Zheng, Megha Vaman Rao, Miao Tan, David P. Meininger
  • Anti-CD47 antibodies
    Patent number: 11352425
    Abstract: The present invention provides anti-CD47 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, ischemic-reperfusion injury, and other diseases.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: June 7, 2022
    Assignee: ABSOS, LLC
    Inventors: John Lippincott, Dana Duey, Larry Green
  • ANTI-CD47 ANTIBODIES AND USES THEREOF
    Publication number: 20220144943
    Abstract: Disclosed herein, in certain embodiments, are anti-CD47 antibodies, nucleic acid polymers encoding the antibodies, and vectors for expressing the same. In some embodiments, also disclosed herein include pharmaceutical compositions comprising the anti-CD47 antibodies and methods of treatment.
    Type: Application
    Filed: February 7, 2020
    Publication date: May 12, 2022
    Inventors: Jason KAHANA, John LIPPINCOTT
  • ANTIBODIES TO TIGIT
    Publication number: 20220064294
    Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Application
    Filed: June 1, 2021
    Publication date: March 3, 2022
    Inventors: Kelsey Sivick GAUTHIER, Nigel Pelham Clinton WALKER, Xiaoning ZHAO, John LIPPINCOTT
  • ANTI-CLAUDIN 18.2 ANTIBODIES
    Publication number: 20210009686
    Abstract: Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 14, 2021
    Inventors: Yuntao SONG, Yi DING, Chen DONG, Zhiwei LI, John LIPPINCOTT, Ping Hui SZU
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20200385473
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 10, 2020
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sung Young KIM, Leonard G PRESTA, Jan-Willem THEUNISSEN
  • BTLA-BINDING ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE
    Publication number: 20200325230
    Abstract: The invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 15, 2020
    Inventors: Brian A. Zabel, John A. Lippincott, Yayue Zheng, Megha Vaman Rao, Miao Tan, David P. Meininger
  • ANTI-CD115 ANTIBODIES
    Publication number: 20200308291
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: John Lippincott, Dana Duey
  • Anti-C10ORF54 antibodies and uses thereof
    Patent number: 10766959
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 8, 2020
    Assignee: Pierre Fabre Medicament
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Anti-CD115 antibodies
    Patent number: 10759861
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 1, 2020
    Assignee: Ablexis, LLC
    Inventors: John Lippincott, Dana Duey
  • Anti-CD115 antibodies
    Patent number: 10723801
    Abstract: The present invention provides anti-CD115 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, autoimmune, and other diseases.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: July 28, 2020
    Assignee: Ablexis, LLC
    Inventors: John Lippincott, Dana Duey
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20200040102
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: July 23, 2019
    Publication date: February 6, 2020
    Applicant: Pierre Fabre Medicament
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • ANTI-CD47 ANTIBODIES
    Publication number: 20190292258
    Abstract: The present invention provides anti-CD47 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic and diagnostic methods for the treatment of cancer, ischemic-reperfusion injury, and other diseases.
    Type: Application
    Filed: November 8, 2017
    Publication date: September 26, 2019
    Inventors: John Lippincott, Dana Duey, Larry Green
  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 10421818
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 24, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta